

**DEPARTURE BAY CAPITAL CORP.  
MANAGEMENT’S DISCUSSION AND ANALYSIS  
FOR THE YEAR ENDED FEBRUARY 28, 2025**

**Background**

This management’s discussion and analysis (“MD&A”) of the operations, results, and financial position of Departure Bay Capital Corp. (“the Company”) for the year ended February 28, 2025 should be read in conjunction with the Company’s audited consolidated financial statements for the same year along with the notes to these same financial statements.

The effective date of this report is June 30, 2025.

The Company’s referenced consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Except as otherwise disclosed, all dollar figures included therein and in the following MD&A are quoted in Canadian dollars. Additional information relevant to the Company’s activities can be found on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

**Company Overview**

Departure Bay Capital Corp. (the “Company”) was incorporated under the Business Corporations Act (British Columbia) on February 16, 2022. The Company is classified as a Capital Pool Company as defined in the TSX Venture Exchange (the “Exchange”) Policy 2.4. The principal business of the Company is the identification and evaluation of a Qualifying Transaction (“QT”) and once identified or evaluated, to negotiate an acquisition or participation in a business subject to receipt of shareholder approval, if required, and acceptance by regulatory authorities. On October 26, 2022, the Company’s common shares were listed on the Exchange under the symbol “DBC.P” and began trading on October 28, 2022.

The head office, principal address and registered office of the Company are located at Suite 228 – 1122 Mainland Street, Vancouver, B.C. V6B 5L1, Canada.

The Company’s continuing operations are dependent upon its ability to identify, evaluate and negotiate an acquisition of an interest in assets or businesses which qualifies as a QT. Such an acquisition or investment will be subject to regulatory approval and may or may not require additional financing. There is no assurance that the Company will be able to complete a QT or that it will be able to secure the necessary financing to complete a QT. If the Company does not meet these requirements, the Exchange may suspend from trading or delist the shares of the Company.

## Initial Public Offering and Qualifying Transaction

The Company completed its initial public offering (“IPO”) on October 26, 2022, and intends to use the net proceeds to identify and evaluate potential Qualifying Transaction (“QT”) pursuant to the policies of the Exchange.

On October 28, 2024, the Company entered into a binding letter of intent (“LOI”) with 9302204 Canada Inc. (“Cheelcare”) pursuant to which the Company proposes to acquire all of the issued and outstanding securities of Cheelcare in exchange for the issuance of securities of the Company, which will result in Cheelcare becoming a wholly-owned subsidiary of the Company (the “Cheelcare Transaction”). The Cheelcare Transaction will result in a reverse take-over of the Company where the existing shareholders of Cheelcare will own a majority of the outstanding common shares of the Company (the “Resulting Issuer”).

The closing of the Cheelcare Transaction is subject to a number of conditions including, but not limited to:

- Satisfactory due diligence review;
- Negotiating and entering into a definitive agreement incorporating the principal terms of the Cheelcare Transaction as described in the LOI;
- Shareholder approval by the Company and Cheelcare, if required;
- The Company completing a consolidation of its issued and outstanding common shares on the basis of three pre-consolidation common shares for each one post-consolidation common share;
- Cheelcare closing a private placement for gross proceeds of not less than \$2,500,000;
- Preparation and filing of documents as required to close the Cheelcare Transaction; and
- Obtaining all regulatory approvals.

In connection with the Cheelcare Transaction, on November 13, 2024, the Company loaned \$25,000 (“Bridge Loan 1”) to Cheelcare. The loan bears an interest rate of 8% compounded annually, is unsecured, and must be repaid with accrued interest within twenty business days after the date of the earlier of:

- the receipt of final approval of the TSX Venture Exchange (the “Exchange”) of the Cheelcare Transaction; or
- the termination of the Cheelcare Transaction pursuant to the terms of the definitive agreement.

On December 13, 2024, the Company loaned a further \$50,000 to Cheelcare (“Bridge Loan 2”) pursuant to the Cheelcare Transaction. The loan bears an interest rate of 8% compounded annually, is secured against the assets of Cheelcare, and must be repaid with accrued interest within twenty business days after the date of the earlier of:

- the receipt of final approval of the Exchange of the Cheelcare Transaction; or
- the termination of the Cheelcare Transaction pursuant to the terms of the definitive agreement.

The principal portion of the loan and related accrued interest is repayable immediately if Cheelcare causes a default pursuant to Bridge Loan 2.

Further to the October 28, 2024 LOI with Cheelcare, the Company entered into a business combination agreement dated February 24, 2025 (the “Definitive Agreement”) with Cheelcare and 16729053 Canada Inc., a wholly-owned subsidiary of Company (“Subco”), pursuant to which the parties will complete a three-cornered amalgamation whereby Subco will amalgamate with Cheelcare (the “Amalgamation”) pursuant to the provisions of the *Canada Business Corporations Act* (“CBCA”), such that upon completion of the transaction (the “Transaction”), the Company will hold all of the issued and outstanding shares in the capital of the corporation resulting from the Amalgamation (post-Transaction, the Company referred to as the “Resulting Issuer”). The Definitive Agreement superseded and replaced the LOI. The Transaction is intended to constitute the Company’s “Qualifying Transaction” (as defined in Policy 2.4 of the Exchange Corporate Finance Manual). Subco was incorporated under the CBCA on February 6, 2025 for the purpose of carrying out the proposed Transaction. Upon completion of the Transaction and subject to the approval of the Exchange, it is expected that the Resulting Issuer will be renamed “Cheelcare Inc.” (or such other substantially similar name as may be determined by Cheelcare and the Company), the board of directors will be reconstituted and the Resulting Issuer will be listed on the Exchange as a Tier 2 Technology Issuer (as such term is defined in the Exchange Corporate Finance Manual).

Immediately prior to the completion of the Transaction, and as a condition to the completion of the Transaction, the Company will consolidate its issued and outstanding common shares on the basis of three (3) pre-consolidation

shares for each one (1) post-consolidation share. In addition, immediately prior to the completion of the Transaction and as a condition to the completion of the Transaction, Cheelcare will split (the “Cheelcare Split”) its issued and outstanding common shares (the “Cheelcare Common Shares”) on such basis of one (1) Cheelcare common share pre-Cheelcare Split for 1.31431707 Post-Split Cheelcare common share.

As a condition to the closing of the Transaction, Cheelcare will have completed a non-brokered private placement (the “Private Placement”) of subscription receipts at a price of \$0.75 per Cheelcare Subscription Receipt (the “Subscription Receipts”) for aggregate gross proceeds of a minimum of \$2,500,000 and up to a maximum of \$3,500,000. Cheelcare closed its Private Placement of Subscription Receipts for aggregate gross proceeds of \$3,499,999.50. Cheelcare closed a first tranche of the Private Placement on December 31, 2024, pursuant to which it issued 4,523,604 Subscription Receipts and a second tranche on January 29, 2025, pursuant to which it issued 143,062 Subscription Receipts. Concurrent with the closing of the Transaction, each Subscription Receipt will automatically convert without any further action or payment of any additional consideration therefor, into one unit of Cheelcare (a “Unit”), with each Unit being comprised of one post-Cheelcare Split common share and one-half of one warrant of Cheelcare, with each whole warrant entitling the holder thereof to acquire one Cheelcare common share (post-Cheelcare Split) at a price of \$1.50 until the date that is 24 months following the closing date of the Transaction, subject to certain acceleration provisions. The proceeds from the Subscription Receipts will be used to fund the general working capital and business requirements of the Resulting Issuer.

In addition to the closing of its Private Placement of Subscription Receipts, Cheelcare also closed a private placement of debentures (the “Debentures”) on January 29, 2025. Certain current insiders of the Company purchased Subscription Receipts in the Private Placement and/or Debentures, as follows: (i) 66,666 Subscription Receipts indirectly acquired by Alan Savage, Chief Financial Officer and director of the Company; (ii) \$50,000 of Debentures purchased directly by Trevor Treweeke, Chief Executive Officer, Corporate Secretary and director of the Company; (iii) \$128,000 of Debentures purchased indirectly by Paul Andreola, director of the Company and (iv) \$25,000 of Debentures purchased indirectly by Jake Bouma, director of the Company.

## **Overall Performance**

The Company was incorporated on February 16, 2022. The Company does not have any operations to the date of this document and, until it completes a Qualifying Transaction, will not conduct any business other than the identification and evaluation of businesses and assets for potential acquisition.

As at February 28, 2025, the Company accumulated deficit of \$238,239. The Company's potential completion of a QT and recurring operating losses and working capital needs may require that it obtain additional capital to continue its operation. Such outside capital may include the sale of additional common shares. During the year ended February 28, 2025, the Company's cash balance decreased to \$30,110 from \$149,595. The decrease is due to auditor fees being paid, along with regulatory costs, and short-term loans to Cheelcare.

There can be no assurance that capital will be available as necessary to meet the Company's needs or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in a significant dilution in the equity interests of its current shareholders.

## **SELECTED QUARTERLY RESULTS**

The following table contains selected financial information for the last eight quarters:

<i>Quarters Ended:</i>	February 28, 2025	November 30, 2024	August 31, 2024	May 31, 2024
	\$	\$	\$	\$
Total expenses <sup>(1)</sup>	35,301	20,176	7,731	2,763
Net loss and comprehensive loss	(35,301)	(20,176)	(7,731)	(2,763)
Basic & diluted loss per share	(0.02)	(0.01)	(0.00)	(0.00)

<i>Quarters Ended:</i>	February 29, 2024	November 30, 2023	August 31, 2023	May 31, 2023
	\$	\$	\$	\$
Total expenses <sup>(1)</sup>	22,320	6,828	11,225	3,422
Net loss and comprehensive loss	(22,320)	(6,828)	(11,225)	(3,422)
Basic & diluted loss per share	(0.01)	(0.00)	(0.01)	(0.00)

(1) Total expenses include professional fees, regulatory and filing fees, administrative, office and bank charges.

During the three and twelve months ended February 28, 2025, the Company had a net loss of \$35,301 and \$65,971 compared to a net losses of \$22,320 and \$43,795 in the comparable periods. The Company's expenses increased in the current three and twelve months period as a result of increased professional fees, and office expenses relating to the facilitating the Cheelcare Transaction.

#### **Additional Disclosure for Venture Issuers without Significant Revenue**

Additional financial information is available in the Company's consolidated financial statements for the year ended February 28, 2025. These statements are available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

The following addresses the specific disclosure requirements for venture issues without significant revenues:

- Capitalized or expensed exploration and development costs – Not applicable
- Expensed research and development costs – Not applicable
- Deferred development costs – Not applicable
- General administrative expenses – the financial information is presented in the Statement of Net and Comprehensive Loss in the financial statements.
- Any material costs, whether capitalized, deferred or expensed, not referred to in (a) through (d) – None.

#### **Profits**

At this time, the issuer is not anticipating profit or revenue from operations. The issuer will report an annual deficit and quarterly deficit and will rely on its ability to obtain equity financing to fund its search for a QT. For information concerning the business of the issuer, please see "Company Overview".

#### **Liquidity**

The Company had a working capital of \$67,316 at February 28, 2025 (February 28, 2024 - \$133,287).

Net cash used in operating activities for the year ended February 28, 2025 was \$44,485 compared to net cash used in operating activities for the year ended February 29, 2024 of \$43,823. The cash used in operating activities for the current period was to pay general and administrative expenses.

Net cash used in investing activities for the year ended February 28, 2025 was \$75,000 compared to nil for the year ended February 29, 2024. The cash used in investing activities for the current period was for the short term loans made to Cheelcare.

### **Capital Resources**

On February 16, 2022, the Company issued 2,000,000 common shares at \$0.05 per share to the directors of the Company for proceeds of \$100,000 which were received through the year ended February 28, 2023.

On March 18, 2022, the Company issued 500,000 common shares at a price \$0.05 per share.

All common shares acquired in the secondary market prior to the completion of a QT by a Control Person, as defined in the policies of the Exchange, are required to be deposited in escrow. Subject to certain permitted exemptions, all securities of the Company held by principals of the resulting issuer will also be subject to escrow.

The Company manages its capital structure and adjusts it, based on the funds available to the Company, in order to support the identification and evaluation of a QT and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. Additional funds may be required to finance the Company's QT. The Company is not subject to any externally imposed capital requirements other than the expenditure restrictions applicable under Policy 2.4, which will apply following the completion of the IPO. These expenditure restrictions limit the Company's on-going expenditures to reasonable expenditures relating to the IPO, reasonable expenses relating to a proposed Qualifying Transaction, assurance and audit fees, escrow agent and transfer agent fees, regulatory filing fees and a maximum of \$3,000 per month for other general and administrative costs. The Company's approach to capital management has not been changed from prior year.

There is no assurance that the Company will be able to identify a suitable business, asset or property as its Qualifying Transaction. Furthermore, even if a QT is identified, there can be no assurance that the Company will be able to complete the transaction.

If the Company identifies a QT, it may be necessary for the Company to seek additional financing. Capital markets may not always be receptive to offerings of new equity from treasury or debt, whether by way of private placements or public offerings, under terms that would be acceptable for the Company.

### **Off-Balance Sheet Arrangements**

The Company has no off-balance sheet arrangements.

### **Transactions between Related Parties**

During the year ended February 28, 2025, there were no related party transactions or balances owing.

### **Proposed Transaction**

Please refer to “Company Overview” discussing the October 28, 2024 LOI, and the February 24, 2025 Definitive Agreement.

## **Critical Accounting Estimates and Judgments**

The preparation of the referenced consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Management believes the estimates and assumptions used in the Company's consolidated financial statements are reasonable; however, actual results could differ from those estimates and could impact future results of operations and cash flows.

The Company's significant accounting judgments and estimates have been applied in the Company's financial statements:

Judgements:

- (i) The evaluation of the Company's ability to continue as a going concern

## **Financial Instruments**

As at February 28, 2025, the Company's financial instruments consist of cash, short term loans, and accounts payable and accrued liabilities. The Company believes that the carrying values of cash, short term loans and accounts payable and accrued liabilities approximate their fair values because of their nature and relatively short maturity dates or durations.

The risk exposure arising from these financial instruments is summarized as follows:

- (a) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a loss for the other party by failing to discharge an obligation. The Company limits its exposure to credit loss for cash by placing its cash with a major financial institution. The Company has exposure to credit risk in the amount of \$75,000 related to the short-term loans to Cheelcare.

- (b) Liquidity risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. The Company's ability to continue to meet its liabilities when due, beyond the current cash balance, is dependent on future support of shareholders through public or private equity offerings. Refer to Note 1 of the consolidated financial statements, Nature of Operations and Going Concern.

- (c) Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or value of its holdings or financial instruments. The Company's activities have only been transacted in Canadian dollars since incorporation; in addition, the Company carries no interest-bearing debt. As such, the Company has minimal market risks facing it at present.

## **Disclosure of Outstanding Share Data**

The Company is authorized to issue an unlimited number of Class A common shares and an unlimited number of Class B preferred shares without par value. No Class B preferred shares have been issued to date.

As at the date of this MD&A, the Company had 4,500,000 common shares issued and outstanding; 200,000 broker warrants; and 450,000 stock options. 2,500,000 common shares and 450,000 stock option held in escrow pursuant to Exchange CPC Policies.

## **New accounting standards and interpretations**

The Company is expected to adopt *IFRS 18 Presentation and Disclosure in Financial Statements* for reporting periods beginning on or after January 1, 2027. The Company will be evaluating the impact of this standard on its financial statements.

## **Risks and Uncertainties**

The Company's financial performance is likely to be subject to the following risks:

1. The Company has not commenced commercial operations, has no assets other than cash. The Company has no history of earnings, and will not generate earnings to pay dividends until at least after the completion of the Qualifying Transaction.
2. Until completion of the Qualifying Transaction, the Company is not permitted to carry on any business other than the identification and evaluation of potential Qualifying Transactions.
3. The Company only has limited funds with which to identify and evaluate potential Qualifying Transactions and there can be no assurance that the Company will be able to identify or complete a suitable Qualifying Transaction.
4. If a Qualifying Transaction is completed, there can be no assurance that an active and liquid market for the Company's common shares will develop and investors may find it difficult to resell the common shares.

## **Disclosure Controls and Procedures**

Disclosure controls and procedures are intended to provide reasonable assurance that information required to be disclosed is recorded, processed, summarized, and reported within the time periods specified by securities regulations and that the information required to be disclosed is accumulated and communicated to management. Internal controls over financial reporting are intended to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements for external purposes in accordance with IFRS.

## **Forward-Looking Statements**

This MD&A contains forward-looking statements. All statements, other than statements of historical fact, constitute "forward-looking statements" and include any information that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including the Company's strategy, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance.

Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. All such forward-looking information and statements are based on certain assumptions and analyses made by the Company's management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. These statements, however, are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed, implied by or projected in the forward-looking information or statements. Important factors that could cause actual results to differ from these forward-looking statements include but are discussed in Risks and Uncertainties.

There can be no assurance that any forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader should not place any undue reliance on forward-looking information or statements. Except as required by law, the Company does not

intend to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events.